Does the media refer more to SNDX or LGND?

In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 6 articles in the media. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Ligand Pharmaceuticals' score of 0.26 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SNDX or SRRK?

In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Scholar Rock. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 2 mentions for Scholar Rock. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Scholar Rock's score of 0.17 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SNDX or MIRM?

In the previous week, Mirum Pharmaceuticals had 29 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Mirum Pharmaceuticals' score of 0.58 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Syndax Pharmaceuticals (SNDX) Competitors

$17.60 -0.62 (-3.40%)

As of 10/2/2026 04:00 PM Eastern

Compare

SNDX vs. LGND, CGON, SRRK, KNSA, and MIRM

Should you buy Syndax Pharmaceuticals stock or one of its competitors? Syndax Pharmaceuticals's main competitors and comparable companies include Ligand Pharmaceuticals (LGND), CG Oncology (CGON), Scholar Rock (SRRK), Kiniksa Pharmaceuticals International (KNSA), and Mirum Pharmaceuticals (MIRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Syndax Pharmaceuticals compare to Ligand Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Syndax Pharmaceuticals presently has a consensus target price of $41.80, suggesting a potential upside of 137.50%. Ligand Pharmaceuticals has a consensus target price of $337.89, suggesting a potential upside of 11.53%. Given Syndax Pharmaceuticals' higher possible upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ligand Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.05	-$285.42M	-$2.51	N/A
Ligand Pharmaceuticals	$268.09M	22.53	$124.45M	$9.35	32.40

In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 6 articles in the media. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Ligand Pharmaceuticals' score of 0.26 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Syndax Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Syndax Pharmaceuticals' net margin of -87.52%. Ligand Pharmaceuticals' return on equity of 20.06% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

Summary

Ligand Pharmaceuticals beats Syndax Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to CG Oncology?

Syndax Pharmaceuticals (NASDAQ:SNDX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Syndax Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

CG Oncology has lower revenue, but higher earnings than Syndax Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.05	-$285.42M	-$2.51	N/A
CG Oncology	$4.04M	1,478.36	-$160.99M	-$2.69	N/A

In the previous week, Syndax Pharmaceuticals had 6 more articles in the media than CG Oncology. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 0 mentions for CG Oncology. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat CG Oncology's score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Syndax Pharmaceuticals	Positive
CG Oncology	Neutral

Syndax Pharmaceuticals currently has a consensus price target of $41.80, suggesting a potential upside of 137.50%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 30.27%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

26.6% of CG Oncology shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Syndax Pharmaceuticals has a net margin of -87.52% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Summary

Syndax Pharmaceuticals beats CG Oncology on 10 of the 15 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Scholar Rock?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Syndax Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Syndax Pharmaceuticals presently has a consensus target price of $41.80, indicating a potential upside of 137.50%. Scholar Rock has a consensus target price of $66.75, indicating a potential upside of 42.60%. Given Syndax Pharmaceuticals' higher possible upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94

In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Scholar Rock. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 2 mentions for Scholar Rock. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Scholar Rock's score of 0.17 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Syndax Pharmaceuticals has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.05	-$285.42M	-$2.51	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

91.1% of Scholar Rock shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Scholar Rock has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Scholar Rock's return on equity of -160.19% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Scholar Rock	N/A	-160.19%	-87.18%

Summary

Syndax Pharmaceuticals and Scholar Rock tied by winning 8 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Kiniksa Pharmaceuticals International currently has a consensus target price of $93.14, suggesting a potential upside of 22.90%. Syndax Pharmaceuticals has a consensus target price of $41.80, suggesting a potential upside of 137.50%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Kiniksa Pharmaceuticals International has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	8.73	$59.01M	$0.97	78.13
Syndax Pharmaceuticals	$172.35M	9.05	-$285.42M	-$2.51	N/A

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Syndax Pharmaceuticals' net margin of -87.52%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Kiniksa Pharmaceuticals International has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Kiniksa Pharmaceuticals International. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Kiniksa Pharmaceuticals International's score of 0.66 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Syndax Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Syndax Pharmaceuticals has a net margin of -87.52% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

In the previous week, Mirum Pharmaceuticals had 29 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Mirum Pharmaceuticals' score of 0.58 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.05	-$285.42M	-$2.51	N/A
Mirum Pharmaceuticals	$521.31M	10.33	-$23.36M	-$14.55	N/A

Syndax Pharmaceuticals presently has a consensus target price of $41.80, indicating a potential upside of 137.50%. Mirum Pharmaceuticals has a consensus target price of $142.56, indicating a potential upside of 71.91%. Given Syndax Pharmaceuticals' higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mirum Pharmaceuticals beats Syndax Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNDX vs. The Competition

Export

Metric	Syndax Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.61B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-7.01	12.93	273.77	26.04
Price / Sales	9.05	1,292.30	607.64	84.84
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	23.78	16.63	10.92	6.30
Net Income	-$285.42M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-3.30%	-3.10%	-2.07%	-1.67%
1 Month Performance	-14.89%	-10.70%	-6.21%	-4.51%
1 Year Performance	12.82%	19.46%	7.45%	2.03%

Syndax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNDX Syndax Pharmaceuticals	2.7513 of 5 stars	$17.60 -3.4%	$41.80 +137.5%	+14.0%	$1.61B	$172.35M	N/A	298	News Coverage Positive News Analyst Forecast
LGND Ligand Pharmaceuticals	3.4385 of 5 stars	$301.52 +0.8%	$337.89 +12.1%	+68.2%	$6.01B	$268.09M	32.25	47
CGON CG Oncology	2.3214 of 5 stars	$67.15 -2.3%	$87.78 +30.7%	+69.1%	$5.95B	$4.04M	N/A	142
SRRK Scholar Rock	2.692 of 5 stars	$48.63 +0.0%	$66.75 +37.3%	+33.0%	$5.92B	N/A	N/A	289
KNSA Kiniksa Pharmaceuticals International	4.3082 of 5 stars	$75.08 -0.3%	$87.38 +16.4%	+102.3%	$5.86B	$677.56M	77.40	366	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNDX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. LGND, CGON, SRRK, KNSA, and MIRM

How does Syndax Pharmaceuticals compare to Ligand Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to CG Oncology?

Summary

How does Syndax Pharmaceuticals compare to Scholar Rock?

Summary

How does Syndax Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. LGND, CGON, SRRK, KNSA, and MIRM

How does Syndax Pharmaceuticals compare to Ligand Pharmaceuticals?

Do analysts prefer SNDX or LGND?

Which has better valuation and earnings, SNDX or LGND?

Does the media refer more to SNDX or LGND?

Which has more volatility and risk, SNDX or LGND?

Do institutionals & insiders hold more shares of SNDX or LGND?

Is SNDX or LGND more profitable?

Summary

How does Syndax Pharmaceuticals compare to CG Oncology?

Which has more risk and volatility, SNDX or CGON?

Which has better valuation & earnings, SNDX or CGON?

Does the media favor SNDX or CGON?

Do analysts rate SNDX or CGON?

Do insiders and institutionals have more ownership in SNDX or CGON?

Is SNDX or CGON more profitable?

Summary

How does Syndax Pharmaceuticals compare to Scholar Rock?

Which has more risk and volatility, SNDX or SRRK?

Do analysts prefer SNDX or SRRK?

Does the media favor SNDX or SRRK?

Which has higher valuation and earnings, SNDX or SRRK?

Do insiders & institutionals have more ownership in SNDX or SRRK?

Is SNDX or SRRK more profitable?

Summary

How does Syndax Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Do analysts prefer KNSA or SNDX?

Which has higher earnings and valuation, KNSA or SNDX?

Do institutionals & insiders hold more shares of KNSA or SNDX?

Is KNSA or SNDX more profitable?

Which has more risk & volatility, KNSA or SNDX?

Does the media refer more to KNSA or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Is SNDX or MIRM more profitable?

Does the media prefer SNDX or MIRM?

Which has more risk and volatility, SNDX or MIRM?

Which has better earnings and valuation, SNDX or MIRM?

Do analysts recommend SNDX or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools